Literature DB >> 2351116

Disparate effect of tamoxifen in rats with experimentally induced endometriosis.

R Kadaba1, C W Simpson.   

Abstract

The effect of tamoxifen on the growth of endometrial implants was examined in rats with experimentally induced endometriosis. Administration of tamoxifen (1 mg/kg x day) for 60 days completely regressed the endometrial implants. When tamoxifen treatment was withdrawn, recurrence of endometrial implants was observed. Ectopic endometrial implants regressed completely 2 months after ovariectomy in rats with experimentally induced endometriosis. Tamoxifen administration (1 mg/kg x day) for 60 days to ovariectomized rats with regressed implants led to complete recurrence of ectopic endometrial implants. In ovariectomized rats administration of tamoxifen antagonized estradiol-enhanced thymidine incorporation into uterine DNA, but tamoxifen per se stimulated thymidine incorporation. This indicates the agonist/antagonist nature of tamoxifen. Treatment of rats with tamoxifen blocked the normal estrous cycle. However, serum progesterone levels were higher during tamoxifen treatment in rats with intact ovaries than in ovariectomized rats. When ovariectomized rats with regressed implants were administered tamoxifen (1 mg/kg x day) and progesterone (10 mg/kg x day) for 60 days, recurrence of ectopic endometrial implants was not observed. These findings suggest that tamoxifen is effective in regressing endometrial implants in rats with experimentally induced endometriosis, and ovarian progesterone may have a facilitatory effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351116     DOI: 10.1210/endo-126-6-3263

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  2 in total

1.  Does gestrinone antagonize the effects of estrogen on endometrial implants upon the peritoneum of rats?

Authors:  Vera Lúcia Rodrigues Lobo; José Maria Soares; Manuel de Jesus Simões; Ricardo dos Santos Simões; Geraldo Rodrigues de Lima; Edmund C Baracat
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

2.  In-vitro osteoblast proliferation and in-vivo anti-osteoporotic activity of Bombax ceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC.

Authors:  Shashi Chauhan; Aditi Sharma; Navneet Kumar Upadhyay; Gajender Singh; Uma Ranjan Lal; Rohit Goyal
Journal:  BMC Complement Altern Med       Date:  2018-08-07       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.